Faruqi and Faruqui, LLP Logo
Share this page

XBiotech, Inc. (XBIT)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In XBiotech, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at XBiotech, Inc. (“XBiotech” or the “Company”) (NASDAQ:XBIT).

The investigation focuses on whether the Company and its executives violated federal securities laws.  Specifically, after market close on April 20, 2017, the Company announced that the European Medicines Agency rendered a negative trend vote after meeting with the Company to discuss the Company’s marketing authorization application for its candidate antibody for the treatment of colorectal cancer.  The negative trend vote indicates that it is unlikely that the Committee for Medicinal Products for Human Use will vote in favor of the marketing authorization application at its formal decision vote. 

Following this news, shares of XBiotech significantly declined, causing harm to investors.

Take Action

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding XBiotech’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    XBiotech, Inc. (XBIT)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 04/21/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.